Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy

摘要: Positron emission tomography (PET) is used routinely to follow therapeutic response in patients treated for non-small cell lung cancer (NSCLC). In responding it generally expected that the observed decrease fluorodeoxyglucose uptake should be similar all lesions. other disease entities though, isolated cases have been documented of asynchronous increases activity metastatic bone lesions ("bone flare") despite evidence or stability Here, we describe four NSCLC which results interim PET scans were misleading due osteoblastic flare phenomenon. cases, with bevacizumab addition standard chemotherapy. All developed worsening their skeletal metastases on PET/CT (computed tomography) analysis (increase activity) apparent stable elsewhere. Subsequent confirmed "worsening" was transient, consistent a response. Awareness phenomena important physicians treating patients, particularly bevacizumab.